Tokyo Tape
Sign in
← Otsuka Holdings

Quarterly report · Q3

4578.TEDINET S100PGE4
Period2022-01-01 → 2022-09-30
Filed2022-11-02
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥1.27T2022-01-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥451.8bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥1.50T2021-01-01 → 2021-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥1.11T2021-01-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥388.6bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income¥114.8bn2022-01-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥47.7bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥158.1bn2021-01-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥47.0bn2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax¥146.0bn2022-01-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥53.2bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥163.6bn2021-01-01 → 2021-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥166.3bn2021-01-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥47.1bn2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥111.0bn2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥41.3bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥125.5bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥126.6bn2021-01-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥35.2bn2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥113.9bn2022-01-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥42.4bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥130.0bn2021-01-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥36.3bn2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥3.19Tat 2022-09-30Cons.Assets IFRS
Total assets¥2.82Tat 2021-12-31Cons.Assets IFRS
Total assets¥2.82Tat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥853.3bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥775.7bnat 2021-12-31Cons.Liabilities IFRS
Net assets / equity¥2.33Tat 2022-09-30Cons.Equity IFRS
Net assets / equity¥2.05Tat 2021-12-31Cons.Equity IFRS
Net assets / equity¥2.02Tat 2021-09-30Cons.Equity IFRS
Net assets / equity¥1.88Tat 2020-12-31dCons.Equity IFRS
Equity (owners)¥2.30Tat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.01Tat 2021-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.98Tat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥477.3bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥410.7bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥448.7bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥356.9bnat 2020-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥171.1bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥228.9bn2021-01-01 → 2021-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥197.2bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥60.4bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥95.3bn2021-01-01 → 2021-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥33.0bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥84.0bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥95.8bn2021-01-01 → 2021-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥83.7bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥204.652022-01-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥76.062022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥231.322021-01-01 → 2021-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥233.52021-01-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥64.972021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥204.632022-01-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥76.042022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥231.152021-01-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥233.342021-01-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥64.82021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio72.1%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.3%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio70.5%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 88
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-01-01 → 2022-09-30¥126.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-07-01 → 2022-09-30¥43.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-01-01 → 2022-09-30¥94.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-07-01 → 2022-09-30¥31.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-01-01 → 2022-09-30¥31.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-07-01 → 2022-09-30¥11.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-01-01 → 2022-09-30¥9.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-07-01 → 2022-09-30¥2.0bn
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-09-30−¥32.0bn
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-09-30−¥11.9bn
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-09-30−¥32.0bn
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-09-30−¥11.9bn
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-09-30−¥34.8bn
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-09-30−¥12.0bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue2022-01-01 → 2022-09-30¥27.0bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue2022-07-01 → 2022-09-30¥10.3bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue external2022-01-01 → 2022-09-30¥27.0bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue external2022-07-01 → 2022-09-30¥10.3bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥18m
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥12m
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentsegment profit2022-01-01 → 2022-09-30¥5.6bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentsegment profit2022-07-01 → 2022-09-30¥3.8bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue2022-01-01 → 2022-09-30¥325.6bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue2022-07-01 → 2022-09-30¥119.9bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue external2022-01-01 → 2022-09-30¥325.6bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue external2022-07-01 → 2022-09-30¥119.9bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥18m
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥7m
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentsegment profit2022-01-01 → 2022-09-30¥49.8bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentsegment profit2022-07-01 → 2022-09-30¥21.6bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentrevenue2022-01-01 → 2022-09-30¥819.3bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentrevenue2022-07-01 → 2022-09-30¥290.0bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentrevenue external2022-01-01 → 2022-09-30¥819.3bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentrevenue external2022-07-01 → 2022-09-30¥290.0bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentsegment profit2022-01-01 → 2022-09-30¥84.5bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentsegment profit2022-07-01 → 2022-09-30¥32.3bn
—segment totalrevenue2022-01-01 → 2022-09-30¥1.30T
—segment totalrevenue2022-07-01 → 2022-09-30¥463.7bn
—segment totalrevenue external2022-01-01 → 2022-09-30¥1.27T
—segment totalrevenue external2022-07-01 → 2022-09-30¥451.8bn
—segment totalrevenue intersegment2022-01-01 → 2022-09-30¥32.0bn
—segment totalrevenue intersegment2022-07-01 → 2022-09-30¥11.9bn
—segment totalsegment profit2022-01-01 → 2022-09-30¥149.7bn
—segment totalsegment profit2022-07-01 → 2022-09-30¥59.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-01-01 → 2021-09-30¥110.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-07-01 → 2021-09-30¥36.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-01-01 → 2021-09-30¥82.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-07-01 → 2021-09-30¥26.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-01-01 → 2021-09-30¥28.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-07-01 → 2021-09-30¥10.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-01-01 → 2021-09-30¥12.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-07-01 → 2021-09-30¥2.8bn
Reconciling Itemsreconcilingrevenue2021-01-01 → 2021-09-30−¥28.5bn
Reconciling Itemsreconcilingrevenue2021-07-01 → 2021-09-30−¥10.4bn
Reconciling Itemsreconcilingrevenue intersegment2021-01-01 → 2021-09-30−¥28.5bn
Reconciling Itemsreconcilingrevenue intersegment2021-07-01 → 2021-09-30−¥10.4bn
Reconciling Itemsreconcilingsegment profit2021-01-01 → 2021-09-30−¥33.6bn
Reconciling Itemsreconcilingsegment profit2021-07-01 → 2021-09-30−¥11.8bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue2021-01-01 → 2021-09-30¥24.1bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue2021-07-01 → 2021-09-30¥8.9bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue external2021-01-01 → 2021-09-30¥24.1bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue external2021-07-01 → 2021-09-30¥8.9bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue intersegment2021-01-01 → 2021-09-30¥17m
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥8m
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentsegment profit2021-01-01 → 2021-09-30¥5.8bn
jpcrp040300-q3r_E21183-000Consumer Productsreportable segmentsegment profit2021-07-01 → 2021-09-30¥2.5bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue2021-01-01 → 2021-09-30¥280.1bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue2021-07-01 → 2021-09-30¥104.8bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue external2021-01-01 → 2021-09-30¥280.0bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue external2021-07-01 → 2021-09-30¥104.7bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2021-01-01 → 2021-09-30¥33m
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥12m
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentsegment profit2021-01-01 → 2021-09-30¥45.8bn
jpcrp040300-q3r_E21183-000Nutraceuticalsreportable segmentsegment profit2021-07-01 → 2021-09-30¥19.0bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentrevenue2021-01-01 → 2021-09-30¥721.0bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentrevenue2021-07-01 → 2021-09-30¥248.5bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentrevenue external2021-01-01 → 2021-09-30¥721.0bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentrevenue external2021-07-01 → 2021-09-30¥248.5bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentsegment profit2021-01-01 → 2021-09-30¥128.0bn
jpcrp040300-q3r_E21183-000Pharmaceuticalsreportable segmentsegment profit2021-07-01 → 2021-09-30¥34.5bn
—segment totalrevenue2021-01-01 → 2021-09-30¥1.14T
—segment totalrevenue2021-07-01 → 2021-09-30¥399.0bn
—segment totalrevenue external2021-01-01 → 2021-09-30¥1.11T
—segment totalrevenue external2021-07-01 → 2021-09-30¥388.6bn
—segment totalrevenue intersegment2021-01-01 → 2021-09-30¥28.5bn
—segment totalrevenue intersegment2021-07-01 → 2021-09-30¥10.4bn
—segment totalsegment profit2021-01-01 → 2021-09-30¥191.8bn
—segment totalsegment profit2021-07-01 → 2021-09-30¥58.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 835
ItemContextValueUnit
Payments for acquisition of subsidiaries inv cf IFRSCurrentYTDDuration－JPY
Net decrease increase in time deposits inv cf IFRSPrior1YTDDuration24416000000JPY
Net decrease increase in time deposits inv cf IFRSCurrentYTDDuration-3376000000JPY
Other inv cf IFRSPrior1YTDDuration1810000000JPY
Other inv cf IFRSCurrentYTDDuration526000000JPY
Net cash provided by used in investing activities IFRSPrior1YTDDuration-33009000000JPY
Net cash provided by used in investing activities IFRSCurrentYTDDuration-60410000000JPY
Payments for purchase of treasury shares fin cf IFRSPrior1YTDDuration-1000000JPY
Payments for purchase of treasury shares fin cf IFRSCurrentYTDDuration-0JPY
Net increase decrease in short term borrowings fin cf IFRSPrior1YTDDuration-211000000JPY
Net increase decrease in short term borrowings fin cf IFRSCurrentYTDDuration2660000000JPY
Proceeds from long term borrowings fin cf IFRSPrior1YTDDuration430000000JPY
Proceeds from long term borrowings fin cf IFRSCurrentYTDDuration1061000000JPY
Repayments of long term borrowings fin cf IFRSPrior1YTDDuration-14122000000JPY
Repayments of long term borrowings fin cf IFRSCurrentYTDDuration-17524000000JPY
Repayments of lease obligations fin cf IFRSPrior1YTDDuration-13834000000JPY
Repayments of lease obligations fin cf IFRSCurrentYTDDuration-14740000000JPY
Dividends paid fin cf IFRSPrior1YTDDuration-55984000000JPY
Dividends paid fin cf IFRSCurrentYTDDuration-55474000000JPY
Other fin cf IFRSPrior1YTDDuration-0JPY
Other fin cf IFRSCurrentYTDDuration－JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration-83724000000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration-84018000000JPY
Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRSPrior1YTDDuration80477000000JPY
Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRSCurrentYTDDuration26642000000JPY
Cash and cash equivalents IFRSPrior2YearInstant356851000000JPY
Cash and cash equivalents IFRSPrior1YearInstant410684000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration11349000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration39963000000JPY
Cash and cash equivalents IFRSPrior1QuarterInstant448678000000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant477290000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember720974000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember280038000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember24098000000JPY
Revenue from external customers IFRSPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember82306000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReportableSegmentsMember1107417000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSPrior1YTDDuration1107417000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember33000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember17000000JPY
Intersegment revenue IFRSPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember28445000000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember28496000000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-28496000000JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E21183-000PharmaceuticalsReportableSegmentMember720974000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E21183-000NutraceuticalsReportableSegmentMember280072000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E21183-000ConsumerProductsReportableSegmentMember24115000000JPY
Revenue IFRSPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember110752000000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember1135914000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2021-12-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass